Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.71 +2.34 (+2.88%)
Official Closing Price Updated: 7:00 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
87 88 Next >
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
5 Top Stocks to Buy in February 2025
All of them have great upside. 
Via The Motley Fool
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
Forecasting The Future: 12 Analyst Projections For Merck & Co
Via Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:MRK.
Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics. 
Via Chartmill
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
Via The Motley Fool
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr. 
Via Investor's Business Daily
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
Via The Motley Fool
Topics Stocks
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment. 
Via Benzinga
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing
Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality. 
Via Benzinga
Topics Lawsuit
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
Price Over Earnings Overview: Merck & Co
Via Benzinga
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target. 
Via Benzinga
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines
Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine. 
Via Investor's Business Daily
Topics Artificial Intelligence
Why Summit Therapeutics Stock Is Jumping Today
Via The Motley Fool
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Earnings Season Scorecard And Fresh Analyst Reports For Chevron, Merck & Others
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation, Merck & Co., Inc., and QUALCOMM Incorporated, as well as two micro-cap stocks CSP Inc. and AMCON... 
Via Talk Markets
Topics Stocks / Equities
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever
The time to step into quality dividend payers is when the crowd forgets there's never a bad time to own a high-quality stock. 
Via The Motley Fool
Topics Stocks
What Lies Ahead In 2025? Slower Growth, More Volatility
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Moderna Shares Spike on H5N1 News—What’s Next for Investors?
MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025 
Via MarketBeat
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.